Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

March 18, 2026 - 20:46

New research delivers a stark warning for patients using popular GLP-1 receptor agonists for Type 2 diabetes: interrupting treatment, even briefly, is associated with a significantly higher risk of serious cardiovascular events and death.

The study indicates that patients who experienced a gap in their GLP-1 medication regimen faced a markedly increased likelihood of suffering a heart attack or stroke compared to those who remained consistent with their prescriptions. Furthermore, the risk of death from any cause was also elevated following a treatment interruption.

GLP-1 drugs, which include medications like semaglutide and liraglutide, are widely prescribed not only for blood sugar control but also for their proven cardiovascular benefits in many patients. This new analysis underscores that those protective effects may diminish quickly if treatment is stopped.

Medical experts stress the importance of adherence and caution patients against discontinuing these medications without direct consultation and guidance from their physician. The findings highlight that maintaining consistent therapy is crucial for managing long-term health outcomes in individuals with Type 2 diabetes, for whom cardiovascular disease is a leading concern. The research adds to the understanding of how to optimize treatment plans for chronic conditions.